Baxter International Inc. 10-K Summary (Fiscal Year Ended Dec 31, 2000)
Business Context and Reporting Period
This report covers the fiscal year ended December 31, 2000, for Baxter International Inc., a global leader in critical therapies for life-threatening conditions. The company operates through three primary segments: Medication Delivery, BioScience, and Renal. Baxter manufactures products in 27 countries and sells in over 100 countries. As of December 31, 2000, the company employed approximately 43,000 people. On February 27, 2001, the Board approved a two-for-one stock split subject to shareholder approval.
Key Financial Metrics
Specific revenue, net income, and cash flow figures are incorporated by reference from the Annual Report to Stockholders and are not explicitly detailed in the text of this 10-K filing. However, the following financial data points are provided:
- Research and Development: $379 million in 2000 (compared to $332 million in 1999).
- Capital Expenditures: $547 million in 2000 (compared to $529 million in 1999).
- Leased Equipment Additions: $101 million in 2000.
- Debt Ratings (as of March 1, 2001): A3 (Moody's), A (S&P), A (Duff & Phelps).
- Market Capitalization: Approximately $27.3 billion (based on Feb 28, 2001 closing price of $92.61).
- Outstanding Shares: 295,263,214 shares as of February 28, 2001.
Note: The filing text does not provide clear values for total revenue, profit margins, or total debt principal.
Material Changes and Developments
Significant operational and strategic changes during the period include:
- Acquisitions: Acquired Sera-Tec Biologicals (80 plasmapheresis centers) in February 2001; completed acquisition of North American Vaccine Inc. and Althin Medical AB in 2000.
- Product Launches: Introduced the Ipump Pain Management System and upgraded the Colleague electronic infusion pump. Launched AGGRASTAT, a global premixed cardiac drug.
- Legal Resolutions: Recorded $29 million of income in 2000 related to mammary implant and plasma-based therapies litigation, primarily due to favorable insurance adjustments.
- Joint Ventures: Formed the Global Healthcare Exchange (GHX) in March 2000; continues a manufacturing joint venture with Gambro AB.
Outlook, Risks, and Contingencies
Management Outlook: Baxter intends to accelerate expansion of higher-margin specialty products outside the U.S. and continue developing new technologies through internal development and acquisitions. The company expects continued pressure on pricing due to industry consolidation and cost containment efforts globally.
Legal Contingencies:
- Mammary Implants: Defendant in 651 lawsuits and 216 claims. A class action settlement (Lindsey) is in place. Management believes a substantial portion of liability will be covered by insurance (over $800 million projected coverage).
- Plasma-Based Therapies: Defendant in lawsuits regarding HIV infections from factor concentrates (1978-1985). Settlements are active in the U.S., Japan, and Spain. A holdback of approximately $15 million (26 million Swiss francs) remains from the Immuno acquisition to cover contingent liabilities.
- Environmental: Named as a potentially responsible party for 16 hazardous-waste sites; estimated exposure for Baxter's remaining six sites is approximately $2 million.
Risks: Key risks include currency fluctuations (over 50% of revenue is international), regulatory changes, patent enforcement challenges, and the impact of competitive pricing.
Investor Verification Checklist
- Verify total revenue, net income, and operating cash flow figures in the incorporated Annual Report to Stockholders (pages 19-27 and 28-48).
- Confirm the status of the two-for-one stock split approval at the May 1, 2001, annual meeting.
- Review the specific segment breakdown of revenue and profit in the "Segment Information" notes (Annual Report pages 46-47).
- Monitor the resolution of the mammary implant and plasma-based therapy litigation to assess potential future charges or insurance recoveries.
- Assess the impact of the U.S. dollar strength on international earnings, given the company's significant global exposure.